ABL Diagnostics, a Euronext-listed leader in molecular diagnostics, has announced an exclusive distribution agreement with Riken Genesis Co. Under this partnership, Riken Genesis will promote and commercialise ABLD’s DeepChek and UltraGene molecular assays across laboratories in Japan, further strengthening its diagnostics portfolio.
Through this collaboration, Riken Genesis will offer an expanded range of real-time PCR assays (qPCR) (UltraGene), including syndromic testing panels. This agreement follows the recently announced licensing and transfer agreement of know-how and IP rights related to real-time polymerase chain reaction (PCR) tests made by ABL Diagnostics’ mother company, reinforcing Riken Genesis' position in molecular diagnostics.
Additionally, the exclusive distribution agreement includes the DeepChek line of PCR assays and proprietary downstream analysis software systems, validated for use with both Capillary Electrophoresis (SANGER) and Next-Generation Sequencing (NGS) workflows.
“As a former distributor in Japan of the products related to the know-how acquired by ABL , we believe this new partnership with ABL Diagnostics will enable us to continue providing our customers with robust qPCR solutions that have a proven track record in Japan, while also incorporating advanced sequencing-based genotyping technologies for microbiology,” said Kenji Iwakabe, President and Chief Executive Officer of Riken Genesis .
Dimitri Gonzalez, Head of Diagnostics at ABL Diagnostics, added: “We are excited to collaborate with Riken Genesis to deliver state-of-the-art qPCR and genotyping solutions to microbiology laboratories in Japan.”
